drugset / Press release
FDA offentliggør fokus for mødet i den rådgivende komite om insulin degludec og insulin degludec/insulin aspart
2012-10-25 · Novo Nordisk A/S · original novonordisk.com ↗
Degludec
Insulin
Insulin degludec/insulin aspart
Insulin degludec/insulin aspart
insulin aspart
insulin degludec
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
insulin degludec/insulin aspart
regular insulin
Novo Nordisk meddelte i dag, at de amerikanske sundhedsmyndigheder, FDA, har offentliggjort information om fokus for mødet i den rådgivende komite den 8. november 2012, hvor registreringsansøgningerne for insulin degludec og insulin degludec/insulin aspart vil blive drøftet. Yderligere information: Medier: Investorer: Mike Rulis Kasper Roseeuw Poulsen Tlf. 3079 3573 Tlf. 4442 4303 [email protected] [email protected] Frank Daniel Mersebach Tlf. 4442 0604 [email protected] Lars Borup Jacobsen Tlf. 3075 3479 [email protected] Selskabsmeddelelse nr. 68 / 2012
The release as fetched from its publisher. novonordisk.com ↗